Thomas Rowland, an executive at ANI Pharmaceuticals (NASDAQ:ANIP), reported the sale of 4,772 shares of common stock in an open-market transaction on March 11, 2026, according to a SEC Form 4 filing. Transaction summary Metric Value Shares sold (direct) 4,772 Transaction value $357,471 Post-transaction shares (direct) 38,730 Post-transaction value (direct ownership) $2.95 million Transaction value based on SEC Form 4 reported price ($74.91). Key questions How does the scale of ...